ConductScience.org, home

Paper30173305

A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.

Wong PKK and 11 others. Curr Rheumatol Rep, 2018. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. Papers, record 30173305. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30173305

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
PubMed
Journal
Curr Rheumatol Rep
PubMed
Year
2018
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.17
iCite
Revised in PubMed
2026-10-12
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wong PKKPeter K K
2Bagga HHanish
3Barrett CClaire
4Chong GGeoff
5Hanrahan PPatrick
6Kodali TTeja
7Marabani MMona
8Prince HMH Miles
9Riordan JJohn
10Swarbrick PPhillip
11White RRay
12Young LLaurel

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
Arthritis, RheumatoidMajor topic
Biological ProductsMajor topic
NeoplasmsMajor topic
Practice Patterns, Physicians'Major topic
Humans
Quality of Life

Source PubMed

Download CSV of topics

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123238979Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.Rheumatology (Oxford)2013https://conductscience.org/library/papers/23238979PubMed
224035250Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.Lancet2013https://conductscience.org/library/papers/24035250PubMed
326755797Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.Ann Rheum Dis2016https://conductscience.org/library/papers/26755797PubMed
422241900The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2012https://conductscience.org/library/papers/22241900PubMed
53207388Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.Ann Rheum Dis1988https://conductscience.org/library/papers/3207388PubMed
624498893Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.Mod Rheumatol2014https://conductscience.org/library/papers/24498893PubMed
722045767Spectrum of cancer risk among US solid organ transplant recipients.JAMA2011https://conductscience.org/library/papers/22045767PubMed
830886989
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study.
BMC Rheumatol2019https://conductscience.org/library/papers/30886989PubMed
922190859Tumor evasion from T cell surveillance.J Biomed Biotechnol2011https://conductscience.org/library/papers/22190859PubMed
1011054684Risk of malignancy among patients with rheumatic conditions.Int J Cancer2000https://conductscience.org/library/papers/11054684PubMed
1126135703Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2015https://conductscience.org/library/papers/26135703PubMed
1212010788Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.Blood2002https://conductscience.org/library/papers/12010788PubMed
131103152An endotoxin-induced serum factor that causes necrosis of tumors.Proc Natl Acad Sci U S A1975https://conductscience.org/library/papers/1103152PubMed
1427589729Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.Int J Mol Sci2016https://conductscience.org/library/papers/27589729PubMed
1519054822Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.Ann Rheum Dis2009https://conductscience.org/library/papers/19054822PubMed
1624012043Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.Semin Arthritis Rheum2014https://conductscience.org/library/papers/24012043PubMed
1726481039
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
BMC Musculoskelet Disord2015https://conductscience.org/library/papers/26481039PubMed
1820525992Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010https://conductscience.org/library/papers/20525992PubMed
1924387057Leflunomide: an immunosuppressive drug with multiple effects on T cell function.Mod Rheumatol2002https://conductscience.org/library/papers/24387057PubMed
2027147709Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.Ann Rheum Dis2017https://conductscience.org/library/papers/27147709PubMed

See all 72 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
39605908Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database.Front Pharmacol2024https://conductscience.org/library/papers/39605908PubMed
37476429Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?J Rheum Dis2022https://conductscience.org/library/papers/37476429PubMed
322076882019 Expert opinion on biological treatment use in inflammatory bowel disease management.Turk J Gastroenterol2019https://conductscience.org/library/papers/32207688PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30173305

GET https://conductscience.org/api/papers/v1/30173305/references?page=2